VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment

Cell Biochemistry and Biophysics

Volumn 69, Issue 1, 2014, Pages 151-156

  Mei, Jiong ^a   Zhu, Xiaozhong ^a   Wang, Zhiyuan ^a   Wang, Zheren ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

MEK ERK pathway; Osteosarcoma; RET; Sorafenib; VEGFR2

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN RET; RAF PROTEIN; RET PROTEIN, HUMAN; SORAFENIB; VASCULOTROPIN RECEPTOR;

ANALOGS AND DERIVATIVES; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OSTEOBLAST; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NIACINAMIDE; OSTEOBLASTS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RAF KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84899426256     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9781-7     Document Type: Article

References (19)

1. Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., et al. (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups [Clinical Trial Comparative Study Multicenter Study]. Journal of Clinical Oncology, 23(34), 8845-8852.
2. Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., et al. (2003). Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group [Multicenter Study Research Support, Non-U. S. Gov't]. Journal of Clinical Oncology, 21(2), 334-341.
3. Smithey, B. E., Pappo, A. S., & Hill, D. A. (2002). C-kit expression in pediatric solid tumors: a comparative immunohistochemical study [Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, P. H. S.]. The American Journal of Surgical Pathology, 26(4), 486-492.
4. McGary, E. C., Weber, K., Mills, L., Doucet, M., Lewis, V., Lev, D. C., et al. (2002). Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 [Research Support, U. S. Gov't, P. H. S.]. Clinical Cancer Research, 8(11), 3584-3591.
5. Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6(2), 572-577.
6. Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001). Discovery of a novel Raf kinase inhibitor [Review]. Endocrine-Related Cancer, 8(3), 219-225.
7. Sridhar, S. S., Hedley, D., & Siu, L. L. (2005). Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics, 4(4), 677-685.
8. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19), 7099-7109.
9. Mitsudomi, T. (2010). Advances in target therapy for lung cancer. Japanese Journal of Clinical Oncology, 40(2), 101-106.
10. Merseburger, A. S., Simon, A., Waalkes, S., & Kuczyk, M. A. (2009). Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer [Review]. Expert Review of Anticancer Therapy, 9(10), 1429-1434.
11. Min, L., He, B., & Hui, L. (2011). Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology, 21(1), 10-20.
12. Mao, W. F., Shao, M. H., Gao, P. T., Ma, J., Li, H. J., Li, G. L., et al. (2012). The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacologica Sinica, 33(10), 1311-1318.
13. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells [Research Support, Non-U. S. Gov't]. Cancer Research, 61(12), 4744-4749.
14. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [Clinical Trial Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, Non-P. H. S.]. Journal of Clinical Oncology, 21(23), 4342-4349.
15. Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., et al. (2008). Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, Non-P. H. S.]. Journal of Clinical Oncology, 26(33), 5352-5359.
16. Feld, R., Sridhar, S. S., Shepherd, F. A., Mackay, J. A., & Evans, W. K. (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review. Journal of Thoracic Oncology, 1(4), 367-376.
17. Wolfesberger, B., Tonar, Z., Gerner, W., Skalicky, M., Heiduschka, G., Egerbacher, M., et al. (2010). The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Research in Veterinary Science, 88(1), 94-100.
18. Yang, S. Y., Yu, H., Krygier, J. E., Wooley, P. H., & Mott, M. P. (2007). High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma,. doi: 10. 1155/2007/95628.
19. Cuccuru, G., Lanzi, C., Cassinelli, G., Pratesi, G., Tortoreto, M., Petrangolini, G., et al. (2004). Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma [Research Support, Non-U. S. Gov't]. Journal of the National Cancer Institute, 96(13), 1006-1014.